Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND
Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
210 participants
Sep 25, 2024
OBSERVATIONAL
Conditions
Summary
Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma/EVs).
Eligibility
Inclusion Criteria6
- Patient aged 18 years or older.
- First diagnosis of uni-focal meningioma of the convexity.
- Macroscopical total resection (Simpson 1-3).
- (Retrospective only):
- Surgery performed between 2007 and 2016;
- availability of FFPE sample and medical records.
Exclusion Criteria6
- Genetic syndromes.
- Diffuse Meningeal Meningiomatosis.
- Patients who underwent experimental treatment in neo-adjuvant setting.
- (Prospective only):
- Previous surgical/medical treatment for another meningioma;
- positive oncological history (e.g., breast cancer).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07282470